The role of antibody-based imaging of cancer by positron emission tomography (PET) has expanded significantly in recent years and is poised to radically alter the way that cancer is diagnosed and treated. However, one hurdle that remains is the potentially harmful radiation dose that comes from these imaging agents, as the long circulation time of antibodies (days to weeks) necessitates the use of radionuclides with comparable physical half-lives (i.e. 89Zr, 124I, etc.). One particularly promising solution is the use of the inverse electron demand Diels-Alder (IEDDA) reaction between a 1,2,4,5-tetrazine (Tz) and a trans-cyclooctene (TCO) for pretargeting. By separately injecting antibody and radioligand and allowing the two to “click” in vivo, overall dose to the patient can be reduced nearly 45-fold. The first half of the dissertation to follow seeks to optimize both antibody and radioligand, while setting the stage for eventual clinical translation. The second half explores the emergence of enzyme-responsive nanomaterials in an attempt to develop a PET imaging agent for MMP-9 activity.
","abstract_html":"<p>The role of antibody-based imaging of cancer by positron emission tomography (PET) has expanded significantly in recent years and is poised to radically alter the way that cancer is diagnosed and treated. However, one hurdle that remains is the potentially harmful radiation dose that comes from these imaging agents, as the long circulation time of antibodies (days to weeks) necessitates the use of radionuclides with comparable physical half-lives (i.e. <sup>89</sup>Zr, <sup>124</sup>I, etc.). One particularly promising solution is the use of the inverse electron demand Diels-Alder (IEDDA) reaction between a 1,2,4,5-tetrazine (Tz) and a <em>trans</em>-cyclooctene (TCO) for pretargeting. By separately injecting antibody and radioligand and allowing the two to “click” <em>in vivo</em>, overall dose to the patient can be reduced nearly 45-fold. The first half of the dissertation to follow seeks to optimize both antibody and radioligand, while setting the stage for eventual clinical translation. The second half explores the emergence of enzyme-responsive nanomaterials in an attempt to develop a PET imaging agent for MMP-9 activity.</p>","abstract_has_math":false,"creators":["Cook, Brendon E"],"institution":"The Graduate School and University Center of The City University of New York","degree_name":"Doctor of Philosophy","degree_level":"Doctoral","degree_discipline":"Chemistry","degree_department":null,"school":null,"contributors":[],"advisors":["Brian M. Zeglis"],"committee_chairs":[],"committee_members":["Jason S. Lewis","Lynn C. Francesconi","Rein V. Ulijn","Kevin H. Gardner"],"year":2018,"date_issued":"2018-09-01T07:00:00Z","date_published":"2018-09-01T07:00:00Z","updated_at":"2026-07-24T01:59:30Z","subjects":["Radiochemistry","Pretargeting","peptide amphiphile"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://academicworks.cuny.edu/gc_etds/2783","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Brian M. Zeglis"]},{"key":"dc:contributor.committeemember","label":"Committee Member","values":["Jason S. Lewis","Lynn C. Francesconi","Rein V. Ulijn","Kevin H. Gardner"]},{"key":"dc:creator","label":"Author","values":["Cook, Brendon E"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2020-09-30T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemistry"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Doctoral"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["The Graduate School and University Center of The City University of New York"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Radiochemistry","Pretargeting","peptide amphiphile"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://academicworks.cuny.edu/gc_etds/2783"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["The role of antibody-based imaging of cancer by positron emission tomography (PET) has expanded significantly in recent years and is poised to radically alter the way that cancer is diagnosed and treated. However, one hurdle that remains is the potentially harmful radiation dose that comes from these imaging agents, as the long circulation time of antibodies (days to weeks) necessitates the use of radionuclides with comparable physical half-lives (i.e. 89Zr, 124I, etc.). One particularly promising solution is the use of the inverse electron demand Diels-Alder (IEDDA) reaction between a 1,2,4,5-tetrazine (Tz) and a trans-cyclooctene (TCO) for pretargeting. By separately injecting antibody and radioligand and allowing the two to “click” in vivo, overall dose to the patient can be reduced nearly 45-fold. The first half of the dissertation to follow seeks to optimize both antibody and radioligand, while setting the stage for eventual clinical translation. The second half explores the emergence of enzyme-responsive nanomaterials in an attempt to develop a PET imaging agent for MMP-9 activity.
"]},{"key":"dc:title","label":"Title","values":["The Development of Novel Platforms for the Imaging of Cancer by Positron Emission Tomography"]}]}],"canonical_facts":{"dc:contributor.advisor":["Brian M. Zeglis"],"dc:contributor.committeemember":["Jason S. Lewis","Lynn C. Francesconi","Rein V. Ulijn","Kevin H. Gardner"],"dc:creator":["Cook, Brendon E"],"dc:date.available":["2020-09-30T07:00:00Z"],"dc:description.abstract":["The role of antibody-based imaging of cancer by positron emission tomography (PET) has expanded significantly in recent years and is poised to radically alter the way that cancer is diagnosed and treated. However, one hurdle that remains is the potentially harmful radiation dose that comes from these imaging agents, as the long circulation time of antibodies (days to weeks) necessitates the use of radionuclides with comparable physical half-lives (i.e. 89Zr, 124I, etc.). One particularly promising solution is the use of the inverse electron demand Diels-Alder (IEDDA) reaction between a 1,2,4,5-tetrazine (Tz) and a trans-cyclooctene (TCO) for pretargeting. By separately injecting antibody and radioligand and allowing the two to “click” in vivo, overall dose to the patient can be reduced nearly 45-fold. The first half of the dissertation to follow seeks to optimize both antibody and radioligand, while setting the stage for eventual clinical translation. The second half explores the emergence of enzyme-responsive nanomaterials in an attempt to develop a PET imaging agent for MMP-9 activity.
"],"dc:identifier":["https://academicworks.cuny.edu/gc_etds/2783"],"dc:subject":["Radiochemistry","Pretargeting","peptide amphiphile"],"dc:title":["The Development of Novel Platforms for the Imaging of Cancer by Positron Emission Tomography"],"thesis:degree_discipline":["Chemistry"],"thesis:degree_level":["Doctoral"],"thesis:degree_name":["Doctor of Philosophy"],"thesis:institution_name":["The Graduate School and University Center of The City University of New York"]},"updated_at":"2026-07-24T01:59:30Z"}